Saturday 17 October 2026
Export HAE’s income statement to Excel — free account
Haemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
118.28
3.01
−2.48%
Follow HAE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
36.59 | 27.76 | 21.96 | 14.17 |
+8 more quarters Free account |
P/S ratio |
2.52 | 1.99 | 2.84 | 1.75 | |
P/FCF ratio |
11.63 | 10.16 | 12.04 | 8.95 | |
P/Operating CF |
65.02 | 37.48 | 40.08 | 20.84 | |
P/B ratio |
4.06 | 3.34 | 4.11 | 2.73 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.22 | 2.72 | 3.27 | 2.22 | |
EV/EBITDA |
15.88 | 13.25 | 11.57 | 8.01 | |
EV/Operating CF |
13.25 | 12.39 | 12.71 | 10.18 | |
EV/FCF |
14.86 | 13.88 | 13.83 | 11.36 | |
Quick Ratio |
1.67 | 1.64 | 1.04 | 0.92 | |
Current Ratio |
3.08 | 2.95 | 1.75 | 1.64 | |
Net Debt/EBITDA |
11.18 | 226.86 | 5.79 | 7.03 | |
Debt/Assets |
49.43% | 50.90% | 36.93% | 37.69% | |
Debt/Equity |
1.40 | 1.53 | 1.01 | 1.08 | |
Asset Turnover |
0.56 | 0.55 | 0.53 | 0.53 | |
Operating CF/Net income |
1.59 | (3.52) | 2.09 | 2.88 | |
Capex/Depreciation |
(0.28) | (0.63) | (0.21) | (0.16) | |
Interest Coverage |
5.81 | (4.28) | 9.08 | 8.12 | |
Research and Development Expense of Revenue |
4.77% | 4.17% | 4.19% | 4.54% | |
Selling, General and Administrative Expense of Revenue |
35.05% | 34.92% | 32.20% | 31.05% | |
Intangible Assets out of Total Assets |
0.46 | 0.46 | 0.41 | 0.42 | |
Share Based Compensation of Revenue |
2.74% | 2.64% | 2.30% | 2.32% | |
Graham Net Nets |
(0.21) | (0.29) | (0.17) | (0.30) | |
Graham Number |
29.18 | 27.77 | 40.00 | 37.16 | |
Earnings Yield |
2.73% | 3.60% | 4.55% | 7.06% | |
Free Cash Flow Yield |
8.60% | 9.85% | 8.30% | 11.17% | |
Revenue per Share |
7.48 | 7.34 | 7.24 | 6.88 | |
Operating CF per Share |
1.15 | 1.50 | 2.00 | 2.34 | |
Capex per Share |
(0.17) | (0.36) | (0.13) | (0.10) | |
Free Cash Flow per Share |
0.98 | 1.14 | 1.87 | 2.24 | |
Cash per Share |
4.92 | 5.20 | 7.77 | 6.23 | |
Shareholders Equity per Share |
18.45 | 16.88 | 19.48 | 17.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.45 | 16.88 | 19.48 | 17.84 | |
Free Cash Flow |
44.65 | 53.81 | 87.65 | 106.43 | |
Working Capital |
547.60 | 552.28 | 403.81 | 351.36 | |
Capital Expenditures |
(7.67) | (17.13) | (5.92) | (4.90) | |
Net Current Asset Value |
(717.47) | (764.73) | (635.76) | (693.30) | |
EV/EBIT |
27.12 | 23.18 | 17.15 | 12.13 | |
Capex to Sales |
0.02 | 0.05 | 0.02 | 0.02 | |
Price to Operating Income |
21.22 | 16.97 | 14.94 | 9.56 | |
| Other line items | |||||
Average Receivables |
208.41 | 209.76 | 203.83 | 210.30 | |
Average Payables |
51.17 | 59.03 | 55.84 | 65.47 | |
Average Inventory |
333.63 | 335.76 | 340.40 | 359.16 | |
Average Assets |
2,413.75 | 2,423.44 | 2,511.08 | 2,483.69 | |
Average Common Equity |
859.70 | 808.58 | 909.16 | 864.01 |
Columns are period end dates